Research ArticleNeuropharmacology
MLi-2, a potent, selective and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition
Matthew J Fell, Christian Mirescu, Kallol Basu, Boonlert Cheewatrakoolpong, Duane E DeMong, J. Michael Ellis, Lynn A Hyde, Yinghui Lin, Carrie G Markgraf, Hong Mei, Michael Miller, Frederique M Poulet, Jack D Scott, Michelle D Smith, Zhizhang Yin, Xiaoping Zhou, Eric M. Parker, Matthew E Kennedy and John A Morrow
Journal of Pharmacology and Experimental Therapeutics September 25, 2015, jpet.115.227587; DOI: https://doi.org/10.1124/jpet.115.227587
Matthew J Fell
Merck Research Laboratories
Christian Mirescu
Merck Research Laboratories
Kallol Basu
Merck Research Laboratories
Boonlert Cheewatrakoolpong
Merck Research Laboratories
Duane E DeMong
Merck Research Laboratories
J. Michael Ellis
Merck Research Laboratories
Lynn A Hyde
Merck Research Laboratories
Yinghui Lin
Merck Research Laboratories
Carrie G Markgraf
Merck Research Laboratories
Hong Mei
Merck Research Laboratories
Michael Miller
Merck Research Laboratories
Frederique M Poulet
Merck Research Laboratories
Jack D Scott
Merck Research Laboratories
Michelle D Smith
Merck Research Laboratories
Zhizhang Yin
Merck Research Laboratories
Xiaoping Zhou
Merck Research Laboratories
Eric M. Parker
Merck Research Laboratories
Matthew E Kennedy
Merck Research Laboratories
John A Morrow
Merck Research Laboratories
Data Supplement
Files in this Data Supplement:
- Supplemental Data - 3 supplemental figures, 1 table.